Pfizer and BioNTech already have the COVID-19 Omicron strain booster vaccine available at their disposal. They are asking the US Food and Drug Administration (FDA) for its Emergency Use Authorization (EUA) for the coming Fall season.
The pharmaceutical company has ready stocks of the new booster shot aimed at combatting the mutated strain, seeking to protect the public further than the original shot.
Pfizer COVID-19 Omicron Booster Shot: Asking FDA's EUA
(Photo : JOEL SAGET/AFP via Getty Images)
This illustration picture taken on November 23, 2020 shows a bottle reading "Vaccine Covid-19" and a syringe next to the Pfizer and Biontech logo. - The European Commission has signed five contracts to pre-order vaccines, among which with the U.S.-German company Pfizer-BioNTech (up to 300 million doses).
Pfizer announced via its press release that it had already applied its latest booster vaccine to the US FDA and aims to protect against the Omicron variant. The American multinational pharmaceutical company is requesting its application for recipients 12 years of age and older, focusing on the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine.
The new booster is a mix of its two initial vaccines, aiming to take on two virus strains under the Omicron variant that manifested earlier this year.
It is also an update to its previous booster releases that mainly focus on the original strain of the SARS-CoV2 virus, also known as the original COVID-19 that struck the world in 2020.
Read Also: Pfizer Found Effective in Children Under 5, Experts to Make Recommendations This Week
Pfizer's Omicron Booster Vaccine: Still a Need?
According to Pfizer's release, the new booster vaccine will focus on a more focused approach towards protecting against COVID's Omicron variant, which is still a significant problem for the world now. Additionally, the booster vaccine is still a need for the public, especially as there are looser restrictions and health guidelines that may spark another surge in COVID cases.
Pfizer's Vaccine Development for COVID
Pfizer is one of the leading pharmaceutical companies that led the charge against COVID-19 when it first arrived two years ago, having a vaccine shot against it after less than a year since the initial lockdowns. Fast forward to 2022, the company made a different shot to protect against the Omicron strain, which the FDA previously reviewed.
The original concoction from Pfizer has significant benefits for those that received it, as researchers claimed that its shots were effective even for the mutated strains that manifested before.
Despite this information, Pfizer still created booster shots that aim to protect better and further the public's benefit from the growing case of COVID-19.
The coronavirus is still rampant, and even though there are no more mask protocols for the public now that there is a significant number of vaccinated individuals, people still need to be cautious.
That being said, a booster to protect against the virus and its strains is still a need for everyone, especially in having a higher tier of protection against COVID-19.
Related Article: Robot From China Can Perform COVID-19 Oral Swab Test in Just 35 Seconds
This article is owned by TechTimes
Written by Isaiah Richard
